Elinzanetant Pooled Safety Analysis Supports FDA Approval Decision for Vasomotor Symptoms, With James A. Simon, MD

Vasomotor symptoms (VMS) associated with menopause affect the majority of women during the menopausal transition, yet many remain undertreated due to contraindications to hormone therapy or patient preference for non-hormonal options. Elinzanetant (Lynkuet^®;Bayer), a selective neurokinin 1,3 receptor, received FDA approval in October 2025 as a non-hormonal treatment for moderate-to-severe VMS and represented a new mechanistic class for this indication.¹

The neurokinin receptor antagonist category has faced scrutiny for hepatic safety, with earlier agents in the class failing to reach the market due to liver toxicity signals. The FDA required liver safety monitoring for the first approved agent in this class. Against that backdrop, characterizing the long-term safety of elinzanetant in a robust dataset was a clinical priority. A post hoc pooled analysis drawing on data from 4 randomized, placebo-controlled trials addressed that question by expanding both the sample size and duration of exposure, with 1 of the 4 studies spanning a full year. The analysis found no new, unexpected, or previously uncharacterized adverse events, with the most commonly reported adverse event being headache, occurring in fewer than 10% of treated subjects compared with approximately 7% in the placebo group.

James A. Simon, MD, medical director and founder of IntimMedicine Specialists in Washington, DC, presented this pooled safety analysis at the 2026 ACOG Annual Clinical and Scientific Meeting. In the video above, Simon discusses the safety findings, what they mean for clinician confidence in elinzanetant, and how first-line providers should contextualize the drug's FDA approval in light of this expanded dataset.